Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VHL | P40337 | 1/20 | 0.40 |
| ▸ | CHRM2 | P08172 | 4/20 | 0.36 |
| ▸ | CHRM4 | P08173 | 4/20 | 0.36 |
| ▸ | CHRM3 | P20309 | 4/20 | 0.36 |
| ▸ | BDKRB2 | P30411 | 12/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.35 |
| ▸ | BDKRB1 | P46663 | 5/20 | 0.35 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29411114 | 0.88 | CHRM3 (0.42) | VHLCHRM2CHRM4CHRM3CHRM1 | |
| SCHEMBL30464314 | 0.86 | CHRM3 (0.41) | VHLCHRM2CHRM4CHRM3CHRM1 | |
| SCHEMBL30697837 | 0.86 | CHRM3 (0.41) | VHLCHRM2CHRM4CHRM3CHRM1 | |
| SCHEMBL29935674 | 0.86 | CHRM3 (0.41) | VHLCHRM2CHRM4CHRM3CHRM1 | |
| SCHEMBL30744924 | 0.86 | BDKRB2 (0.37) | VHLBDKRB2BDKRB1 | |
| SCHEMBL10624291 | 0.84 | VHL (0.42) | VHLCHRM2CHRM4CHRM3BDKRB2 | |
| SCHEMBL30097968 | 0.83 | VHL (0.43) | VHLCHRM2CHRM4CHRM3BDKRB2 | |
| SCHEMBL30558187 | 0.82 | FAP (0.42) | — | |
| SCHEMBL29935662 | 0.82 | ITGB3 (0.44) | BDKRB2BDKRB1 | |
| SCHEMBL30558194 | 0.81 | FAP (0.40) | CHRM2CHRM4CHRM3CHRM1CHRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240108598-A1 | Danegaptide for Use in the Treatment or Prevention of a Kidney Disease | BREYE THERAPEUTICS APS (DK) | 2024-04-04 | — | — | US | disclosed |
| EP-4291178-A1 | DANEGAPTIDE FOR USE IN THE TREATMENT OR PREVENTION OF A KIDNEY DISEASE | Breye Therapeutics ApS (DK) | 2023-12-20 | — | — | EP | disclosed |
| CN-116963731-A | Danegapeptide for treating or preventing kidney disease | 布雷耶疗法有限公司 | 2023-10-27 | — | — | CN | disclosed |
| WO-2022171525-A1 | DANEGAPTIDE FOR USE IN THE TREATMENT OR PREVENTION OF A KIDNEY DISEASE | CIANA THERAPEUTICS APS (DK) | 2022-08-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240108598-A1 | Danegaptide for Use in the Treatment or Prevention of a Kidney Disease | REN, DNPEP, SLC5A1 | VHL 474/4885CHRM2 4622/4885CHRM4 4559/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.